Clinical impact of volume of disease and time of metastatic disease presentation on patients receiving enzalutamide or abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer

BACKGROUND: Metastatic castration-resistant prostate cancer remains a challenging condition to treat. Among the available therapeutic options, the androgen receptor signaling inhibitors abiraterone acetate plus prednisone (AA) and enzalutamide (Enza), are currently the most used first-line therapies...

Descripción completa

Detalles Bibliográficos
Autores principales: Nuzzo, Pier Vitale, Pederzoli, Filippo, Saieva, Calogero, Zanardi, Elisa, Fotia, Giuseppe, Malgeri, Andrea, Rossetti, Sabrina, Valenca Bueno, Loana, Andrade, Livia Maria Q. S., Patrikidou, Anna, Mestre, Ricardo Pereira, Modesti, Mikol, Pignata, Sandro, Procopio, Giuseppe, Fornarini, Giuseppe, De Giorgi, Ugo, Russo, Antonio, Francini, Edoardo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896712/
https://www.ncbi.nlm.nih.gov/pubmed/36737752
http://dx.doi.org/10.1186/s12967-022-03861-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9896712/
https://www.ncbi.nlm.nih.gov/pubmed/36737752
http://dx.doi.org/10.1186/s12967-022-03861-2

Ejemplares similares